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Abstract
Background: RNA transfection into dendritic cells (DCs) is widely used to achieve antigen
expression as well as to modify DC properties. CD40L is expressed by activated T cells and
interacts with CD40 receptors expressed on the surface of the DCs leading to Th1 polarization.
Previous studies demonstrated that ectopic CD40L expression via DNA transfection into DCs can
activate the CD40 receptor signal transduction cascade. In contrast to previous reports, this study
demonstrates that the same effect can be achieved when RNA encoding CD40L is electroporated
into DCs as evidenced by secretion of IL-12. To achieve higher levels of IL-12 secretion, a
systematic approach involving modification of coding and noncoding regions was implemented to
optimize protein expression in the DCs for the purpose of increasing IL-12 secretion.
Results: Site-directed mutagenesis of each of the first five in-frame methionine codons in the
CD40L coding sequence demonstrated that DCs expressing a truncated CD40L protein initiated
from the second methionine codon secreted the highest levels of IL-12. In addition, a post-
transcriptional method of capping was utilized for final modification of the CD40L RNA. This
method enzymatically creates a type I cap structure identical to that found in most eukaryotic
mRNAs, in contrast to the type 0 cap incorporated using the conventional co-transcriptional
capping reaction.
Conclusion:  The combination of knocking out the first initiation methionine and post-
transcriptional capping of the CD40L RNA allowed for approximately a one log increase in IL-12
levels by the transfected DCs. We believe this is a first report describing improved protein
expression of post-transcriptionally capped RNA in DCs. The post-transcriptional capping which
allows generation of a type I cap may have broad utility for optimization of protein expression from
RNA in DCs and other cell types.
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Background
RNA transfection into Dendritic Cells (DCs) is widely
employed to achieve antigen expression [1]. RNA-trans-
fected DCs are potent immune stimulators that have been
tested in several clinical trials in cancer patients [2]. Trans-
fection of DCs with RNA has several advantages over other
platforms of antigen delivery such as DNA or viral vector-
encoded antigens. Conditions may be optimized for cyto-
plasmic delivery of the RNA and together with transient
expression and rapid degradation it may contribute to the
safety of DC-based immunotherapy.
Successful protein expression from transfected RNA
depends on transfection efficiency, translation compe-
tence, and stability of the transfected RNA. A 5' cap struc-
ture and 3' poly(A) tail are essential components for RNA
translation in eukaryotic cells. Mockey et. al. demon-
strated that a poly(A) tail of 100 nucleotides and a
5'ARCA cap analogue act synergistically to produce high
protein expression in dendritic cells [3]. Holtkamp et al.
reported that a longer poly(A) tail of 120 A residues as
opposed to a more conventional poly(A) tail of 64 bases
achieves higher protein expression levels. Furthermore,
the 3' ends of the transfected RNA molecules were modi-
fied with a non-translated region from the β-globin gene
of X. laevis. [4]. Together these modifications resulted in
greater protein expression in DCs allowing for increased
cell-surface presentation of epitopes and better induction
of T cell responses.
In addition to antigen-MHC complexes the immunopo-
tency of DCs is dependent on high levels of co-stimulatory
molecules and secreted cytokines. Together, these ele-
ments conspire to induce antigen-specific T helper cell 1
(Th1) and cytotoxic T lymphocyte (CTL) responses. Trans-
fection of DCs with RNA encoding for a pro-inflammatory
cytokine can modify the DC phenotype to enable these
desirable properties. For example, DCs co-transfected
with tumor antigen RNA and IL-12 mRNA were shown to
induce higher numbers of tumor-specific CTLs with
greater functional avidity compared to those transfected
with tumor antigen mRNA alone [5].
In the present study IL-12 secretion by DCs was achieved
by a different approach involving transfection of the DCs
with CD40L RNA. CD40L is normally expressed tran-
siently on the surface of activated CD4+ T cells [6] and
mediates interactions with cells such as DCs that express
its receptor, CD40 [7]. The CD40L molecule interacts with
CD40 expressed on immature DCs (iDCs) and other anti-
gen presenting cells delivering a contact-dependent signal
that drives DC maturation which enhances immunopo-
tency [8]. CD40L is essential for the generation of CTL
responses by RNA-transfected DCs [9]. Also, CD40L
expressed in DCs from a Lentiviral construct induces phe-
notypic maturation as measured by up-regulation of the
surface markers CD83, CD80, and MHC I, as well as secre-
tion of IL-12 cytokine [10].
Here we demonstrate that expression of CD40L from
transfected RNA likewise leads to increased maturation of
DCs and induction of IL-12. Furthermore, additional
optimization of the CD40L RNA was undertaken to
achieve greater levels of the CD40L protein expression
which in turn induce higher levels of IL-12 cytokine secre-
tion. The first of these modifications was to the CD40L
coding sequence where the initiation of translation from
the second in-frame methionine codon led to greater lev-
els of protein expression and consequently induced
higher levels of IL-12 secretion. The other modifications
we explored were not specific to the CD40L coding
sequence and involved enzymatically adding a long
poly(A) tail and post-transcriptional capping of the RNA.
In eukaryotic cells, nascent mRNAs are modified with a
cap structure early during their transcription, when the
transcript reaches 20–30 nucleotides in length [11]. First,
the 5' terminal pppN of the RNA transcript is converted to
5' GpppN by a bi-functional capping enzyme containing
both RNA 5'-triphosphatase and guanylyltransferase
activities [12]. The GpppN moiety is subsequently meth-
ylated by a second enzyme containing (guanine-7)-meth-
yltransferase activity to form the monomethylated
m7GpppN Type 0 cap structure. The Type 0 cap is then
converted to an m7GpppN Type 1 structure in the nucleus
by 2'-O-methylation [13]. When RNA molecules are enzy-
matically synthesized in vitro using most commercially
available kits, 5' capping occurs by a very different mech-
anism. Capping does not occur after synthesis of the tran-
script, but rather occurs concurrently with the initiation of
transcription and is referred to here as "co-transcriptional
capping". During the in vitro transcription reaction, the
dinucleotide cap analog m7G(5')ppp(5')G (referred to
from here on as m7G) is substituted for a portion of the
GTP nucleotide in the reaction and transcription tem-
plates from which the RNA is transcribed are engineered
such that the first nucleotide transcribed is a guanosine.
Consequently, RNA transcription can be initiated with the
cap analogue instead of GTP in a fraction of the mole-
cules. A molar excess of cap analogue relative to GTP
drives the reaction toward preferential incorporation of
the cap dinucleotide at the first position of the transcript.
The products of this type of transcription reaction are
always mixtures of uncapped and capped RNAs resulting
from initiation of synthesis with either GTP or the cap
analogue, respectively. Uncapped molecules present in a
synthetic mRNA preparation are typically not able to be
translated upon transfection into eukaryotic cells
(reviewed in [14]). In addition, the cap stabilizes the RNA
since uncapped RNA is more susceptible to degradationBMC Molecular Biology 2008, 9:90 http://www.biomedcentral.com/1471-2199/9/90
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by exonucleases in cells than the same RNA with an
m7GpppN cap structure [15]. Therefore, the effective con-
centration of active molecules present in any preparation
of co-transcriptionally capped RNA is less than 100% and
is directly linked to the RNA capping efficiency achieved
during the transcription reaction. The effective concentra-
tion of co-transcriptionally capped RNAs with the stand-
ard m7G cap analogue is further reduced because the cap
analogue is able to be incorporated in the reverse
(Gpppm7G) orientation up to 50% of the time [16].
Based upon the structural characterization of the interac-
tion between the 5' mRNA cap and the protein synthesis
machinery, it is expected that RNAs with a reverse cap ori-
entation are not competent for translation [17,18]. Con-
sidering the issues of both capping efficiency and cap
orientation, it is apparent that in a given preparation of
co-transcriptionally capped RNA only a fraction of the
RNA actually provides an active template for protein syn-
thesis. The problem of cap analogue orientation in co-
transcriptionally capped RNAs was addressed by Stepin-
ski, et al. with the synthesis and characterization of the
novel "anti-reverse" cap analog 7-methyl (3'-O-methyl)
GpppG. This anti-reverse cap analog (ARCA) is incapable
of being incorporated in the reverse orientation and thus
gives rise to co-transcriptionally capped RNA preparations
in which all capped transcripts should be competent for
translation [19]. While most of literature on mRNA
expression optimization utilizes ARCA [3-5], we
attempted to further improve the translation competence
of RNA by utilizing a method that poduces nearly 100%
capped RNA. This process makes use of the Vaccinia Virus
Capping Enzyme (VCE) which possesses all three enzy-
matic activities required to build an m7G-cap on the 5'
end of synthetic mRNA molecules. These activities, RNA
5'-triphosphatase, guanylyltransferase, and guanine-7-
methyltransferase, use GTP as a substrate [20-22] and are
now commercially available reagents. The process by
which the m7G cap is assembled on an uncapped syn-
thetic RNA by the VCE is referred to here as "post-tran-
scriptional capping" and results in RNA caps that are
exclusively in the correct orientation. Post-transcriptional
capping can also be used to assemble a 5' ARCA cap on
RNA if 3'-O-Methyl GTP is substituted for the GTP precur-
sor. In addition a type I cap may be created by adding a
second Vaccinia enzyme, 2' O methyltransferase, to the
capping reaction. RNA carrying type I caps are reported to
have enhanced translation efficiency compared to those
modified with the type 0 caps. Furthermore, most eukary-
otic RNAs have type I caps. Thus, the ability to generate
type I RNA is a significant improvement over traditional
methods of RNA capping. To our knowledge this is the
first report documenting expression of RNA modified
with Type I cap in the DCs. Since this RNA modification
in not gene sequence-specific, it may be broadly applica-
ble for increasing protein expression from any synthetic
RNA molecule.
Results
DCs electroporated with CD40L RNA induce IL-12 
cytokine
Since antigen loading of DCs is achieved via RNA transfec-
tion, the antigen payload can be conveniently supple-
mented with the CD40L-encoding RNA. Figure 1 shows
that iDCs matured with the commonly used cytokine
cocktail consisting of TNFα, IL1β, IL6 and PGE2 do not
secrete IL-12, but instead they release low levels of IL-10.
In contrast, IL-12 is detected in the supernatants of CD40L
RNA-transfected cells from 8 hours post-transfection (Fig-
ure 1).
A dose response experiment between the mass of RNA
electroporated into iDCs and the maturation phenotype
was performed (Figure 1). The levels of expression of the
maturation markers, CD80 and CD83, as well as the
amount of secreted IL-12, directly correlated with the
amount of CD40L RNA transfected (unpublished data).
These data support earlier observations that CD40L RNA
expressed ectopically in DCs induce DC maturation and
induction of IL-12 [10]. The level of IL-12 secretion varied
from donor to donor. Examples of IL-12 variability
observed using this method are summarized in Table 1. A
wide range of IL-12 cytokine production as a function of
donor to donor variation is well documented by others
[23]. However, unlike the previous report, we achieve the
effect from transiently expressed RNA rather than recom-
binant lentivirus transduction. Although the desired effect
of DC maturation and Th1 polarization was achieved, fur-
ther optimization of expression was performed.
Examination of the 5' Untranslated Sequence within 
CD40L RNA
CD40L mRNA stability is known to be regulated in T-cells
through sequence elements within the 3' UTR [24]. Dur-
ing the original cloning of the CD40L transcription tem-
plate, the coding region was PCR-amplified from an
activated T-cell cDNA library and only minimal 5' and 3'
UTR sequences were included. The majority of the UTR
sequences flanking the transcribed CD40L coding region
were therefore plasmid sequences. As a first step toward
optimization of the CD40L RNA sequence, the 5'UTR
region of the RNA was examined for elements that may be
unfavourable with regard to mRNA stability or translation
initiation. It was noted that the 5' UTR contained three
potential ATG translation initiation codons upstream of
the natural CD40L initiation codon (Figure 2), none of
which are in the correct reading frame. It is known that
such "upstream ATGs" can compete with the proper ATG
codon for initiation of translation thereby reducing theBMC Molecular Biology 2008, 9:90 http://www.biomedcentral.com/1471-2199/9/90
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rate and accuracy of translation initiation [25]. We postu-
lated that such competition between potential translation
initiation sites in the CD40L RNA may lead to suboptimal
translation efficiency or inaccurate initiation in trans-
fected DCs and account for the inconsistent expression of
CD40L protein at levels sufficient for high IL-12 induc-
tion.
In vitro transcribed RNAs were prepared from each of the
three plasmid templates listed in Figure 2. The RNAs were
capped co-transcriptionally with either m7G or ARCA cap
analogues. These RNAs contained either a 64A tail gener-
ated from in vitro transcription from a poly(T) containing
DNA template or were polyadenylated after the transcrip-
tion reaction in which the poly(A) tails were greater than
200 nucleotides. Four hours post-electroporation into
DCs, CD40L protein expression was measured and
secreted IL-12 cytokine levels were assayed after overnight
incubation (Figure 3). Intracellular staining with anti-
CD40L antibody indicates that the ARCA-capped CD40L
ΔXE RNA is translated at the highest level relative to the
other RNAs and also relative to the original CD40L RNA.
For each distinct RNA sequence, comparison of ARCA-
and m7G-capped RNAs demonstrates that ARCA-capped
RNAs produce higher levels of CD40L protein. Addition-
ally, CD40L+5'UTR RNA with a long poly(A) tail is trans-
lated to a higher level than the same RNA with a 64
nucleotide poly(A) tail. Interestingly, the results in Figure
3 (panel B) demonstrate that protein expression data at 4
hours post-transfection does not linearly correlate with
the level of IL-12 secreted by the same cells at 24 hours
post-transfection. In some cases, similar levels of CD40L
protein expression induced dramatically different levels of
secreted IL-12 (compare the +5'UTR RNA to +5'UTR+64A
in Figure 3, panel B). Nevertheless, the ELISA results indi-
cate that the ARCA-capped CD40L ΔXE RNA induces the
highest level of IL-12 secretion, consistent with the pro-
tein expression data. The finding that the ΔXE RNA, which
lacks the "upstream ATGs", is translated more efficiently
and induces higher levels of cytokine secretion than
CD40L RNA is in agreement with the idea that the
"upstream ATG's" in the 5' UTR of the WT RNA interfere
with its translation. The presence of the naturally occur-
ring CD40L untranslated region in the CD40L+5'UTR
RNA decreased the RNA's activity relative to the current
wild-type RNA. Consistent with previous findings for the
DCs electroporated with CD40L RNA secrete IL-12 Figure 1
DCs electroporated with CD40L RNA secrete IL-12. Panel A: Cytokine secretion profile of DCs transfected with 2 μg/
million DC eGFP RNA and matured with the cytokine cocktail. Panel B: time course for the secretion of IL-10 versus IL-12 for 
DCs matured by transfection with 4 μg/million DC CD40L RNA and cultured in IFN-γ/PGE2. Panel C: IL-10 and IL-12 release 
as well as expression of the DC maturation markers, CD80 and CD83 from immature DC transfected with a range CD40L 
RNA concentrations, and immediately matured in the presence of IFN-γ.
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Table 1: IL-12 cytokine levels in the supernatants of 
electroporated DCs
IL-12, pg/mL
cellular material used CD40L WT CD40L DXE *Fold change
donor 1 326 8068 24.7
donor 2 31076 133712 4.3
donor 3 5717 35796 6.3
donor 4 2417 36572 15.1
donor 5 8085 58532 7.2
donor 6 7207 20954 2.9
*fold-increase in IL-12 detected by Elisa in DC supernatants 24 hrs 
post electroporation with CD40LDXE RNA compared to WT RNABMC Molecular Biology 2008, 9:90 http://www.biomedcentral.com/1471-2199/9/90
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wild-type RNA, the +5'UTR RNA appears more active in
inducing IL-12 expression when it contains an ARCA cap
and a long poly(A) tail. However, since the naturally
occurring CD40L 5' UTR did not elevate expression of
CD40L RNA from the original construct this modification
was no longer studied.
Optimization of initiator codon and open reading frame
Examination of the CD40L coding sequence revealed
more in-frame ATG codons (in addition to the natural ini-
tiator ATG) within the first 108 nucleotides transcribed
(Figure 4, panel A). In vitro translation products of CD40L
ΔXE RNA reveal two polypeptide bands (Figure, 4 panel
B). The upper band migrates with the expected mobility
for full length protein whereas the lower molecular weight
polypeptide may be a product of initiation at one of
downstream in-frame Methionine codons.
Closer inspection of the sequence surrounding the natural
ATG codon for CD40L translation initiation revealed that
Nucleotide sequence preceding CD40L initiator methionine in various CD40L RNA transcription templates Figure 2
Nucleotide sequence preceding CD40L initiator methionine in various CD40L RNA transcription templates. 
Upper case: T7 promoter sequence; lower case: the sequence of 5'UTR; Upper case italics: accurate CD40L initiation codon; 
Bold lower case: upstream initiator codons which are not natural initiator codon for CD40L; Underline: the natural CD40L 
untranslated sequence (5'UTR).
(A)  pCR2.1 CD40L 
TAATACGACTCACTATAGGGcgaattgggccctctagatgcatgctcgagcggccgccagtgtgatggatatctgcag
aattcggcttgcATG 
 
(B)  pCR2.1 CD40L  XE 
TAATACGACTCACTATAGGGcgaattgggccctctagatctgcagaattcggcttgcATG 
 
(C)  pCR2.1 CD40L +5'UTR 
TAATACGACTCACTATAGGGcgaattgggccctctagatctgcagaattcttctctgccagaagataccatttcaactttaa
cacagcATG 
 
CD40L protein expression and IL-12 cytokine secretion in DC cultures transfected with various CD40L RNAs Figure 3
CD40L protein expression and IL-12 cytokine secretion in DC cultures transfected with various CD40L RNAs. 
Panel A: intracellular staining of DCs with anti-CD40L antibody at 4 hours post-electroporation with the RNAs. Panel B: 
cytokine levels measures in DC culture supernatants after overnight incubation. GFP is used as a negative control RNA. Type 
of cap analogue is indicated by shading back: ARCA and hatched m7G. All RNAs in this experiment were capped co-transcrip-
tionally. All RNAs were polyadenylated in a post-transcriptional reaction and contained >150 nucleotide long poly(A) tail, 
except for CD40L+5'UTR 64A. For this RNA poly(A) tail was obtained in a transcription reaction by transcribing from tem-
plates containing poly(T) stretch after CD40L coding region. 5'UTR 64A+polA tail designates the RNA which in addition to 64 
long poly(A) tail were post-transcriptionally polyadenylated. In this case poly(A) tail was >210 nucleotide long.
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the Kozak sequence surrounding the translation start site
is not optimal. The Kozak sequence is a defined consensus
sequence surrounding the ATG initiation codon in
eukaryotic mRNAs that mediate efficient initiation of
translation by ribosomes [26]. Figure 5 (Panel A) shows a
comparison of the eukaryotic Kozak consensus sequence
(initiator codon at positions +1 through +3) with the
same 5' region in the CD40L sequence. The residue at
position +4 cannot be modified without affecting the
CD40L coding sequence, and therefore was not manipu-
lated. The three nucleotide substitutions shown in Figure
5 (positions -4, -3, and -2) were engineered into the
pCR2.1 CD40L ΔXE plasmid to create pCR2.1 CD40L ΔXE
+ Kozak. Site-directed mutagenesis was performed on the
pCR2.1 CD40L ΔXE plasmid in order to change the first
CD40L ATG codon to GCG, thereby generating the
pCR2.1 CD40L ΔXE-MET1 plasmid. It was predicted that
this mutation would result in translation initiation from
an internal ATG codon within the ΔXE-MET1 RNA. It was
also hypothesized that such internal initiation would
result in predominant expression of the smaller of the two
CD40L polypeptide species observed in the in vitro trans-
Sequence analysis of coding CD40L protein Figure 4
Sequence analysis of coding CD40L protein. Panel A: Amino acid sequence of the human CD40L full length polypeptide. 
In frame internal methionine residues are in bold and underlined. Panel B. SDS-Page Analysis of CD40L polypeptides translated 
in vitro. Lane 1: CD40L ΔXE; Lane 2: no RNA template control; Lane 3: control of irrelevant positive RNA translation.
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Analysis of initiator methionine codon for Kozak composition and its influence on initiation of translation Figure 5
Analysis of initiator methionine codon for Kozak composition and its influence on initiation of translation. Panel 
A. Comparison between the eukaryotic Kozak consensus sequence and the sequence surrounding the CD40L translation initi-
ation site. Nucleotides critical for efficient translation initiation are highlighted. Nucleotide substitutions predicted to enhance 
CD40L translation initiation without modifying the coding region are shown in red. Panel B. Correlation between CD40L small 
isoform expression and IL-12 induction. Graph demonstrates quantitative assessment of level of IL-12 cytokine secretion and 
below are shown SDS PAGE analysis of translation products. WT: wile type CD40L RNA, +Kozak: CD40L sequence with opti-
mized first methionine codon; -Me1: CD40L sequence with knock out of first naturally occurring initiator methionine codon.
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lation reaction (Figure 4, panel B). RNAs transcribed from
these templates were assayed for the ability to induce IL-
12 expression in the DC transfection assay (Figure 5 Panel
B). In addition, the RNA was translated in vitro in the pres-
ence of 35S-labeled methionine and analyzed by SDS-
PAGE and autoradiography.
We altered the sequence immediately upstream of the
translation initiation site such that it more closely
matches the optimal Kozak consensus sequence. As pre-
dicted, data presented in Figure 5 shows that this modifi-
cation results in the synthesis of predominantly full-
length protein. Surprisingly, this modification does not
render the ΔXE + Kozak RNA more effective for induction
of IL-12 expression compared to the CD40L RNA. CD40L
protein expression measured at 4 hours post-electropora-
tion displayed a similar trend (Data not shown). Interest-
ingly, the CD40L-Met 1 RNA produced a single
popypeptide migrating with the apparent mobility of the
smaller polypeptide obtained in in vitro translation of a
full length CD40L RNA. This RNA induced higher levels of
IL-12 than CD40L RNA (Figure 5 panel B).
The lower relative molecular weight of this smaller, poten-
tially more active polypeptide is consistent with its trans-
lation being initiated at one of the internal, in-frame
methionine residues within the 5' end of the coding
sequence. However, from this experiment the particular
methionine residue at which protein synthesis initiates
could not be delineated. Therefore, each of the next three
CD40L methionine codons were mutated consecutively
in the pCR2.1 CD40L-MET1 background to create the fol-
lowing templates: pCR2.1 CD40L-MET1,2; pCR2.1
CD40L-MET1,2,3; and pCR2.1 CD40L-MET1–4. ARCA-
capped, polyadenylated RNAs were prepared from each of
these transcription templates for analysis by in vitro trans-
lation and the DC transfection assay.
In vitro translation of RNAs transcribed from all templates
in the presence of 35S-methionine demonstrated that only
the ΔXE-MET1 RNA encodes a polypeptide species with a
relative mobility equal to that of the smaller CD40L iso-
form (Figure 6 Panel A). The CD40L ΔXE-MET1,2 and
ΔXE-MET1,2,3 RNAs both encode polypeptides of even
lower molecular weight consistent with translation initia-
tion at the fourth ATG codon. The CD40L ΔXE-MET1–4
RNA was not translated efficiently in vitro. These observa-
tions suggest that in vitro translation of the small CD40L
isoform is initiated at the second ATG codon within the
CD40L coding sequence. In transfected DCs, only the
CD40L ΔXE-MET1, and ΔXE-MET1,2 were translated into
detectable amounts of CD40L protein and the level of
protein expression from the next RNA, ΔXE-MET1,2,3,
was greatly reduced (Figure 6, panel B). This difference
between the in vitro and in vivo expression data may sug-
gest that the monoclonal antibody used for protein detec-
tion in DCs recognizes an amino-terminal epitope that
overlaps the mutated region of the protein encoded by
CD40L  ΔXE-MET1,2,3. Alternatively, the epitope may
become unavailable for antibody binding as a result of the
-MET1,2,3 mutation. It is also possible that the ability of
the RNAs to be translated in Wheat Germ Extracts does
not accurately reflect the ability of the RNAs to be trans-
lated in DCs.
Although the ΔXE-MET1,2 RNA is capable of being trans-
lated into detectable protein in DCs, this RNA was not
able to induce IL-12 secretion (Figure 6 panel C).
Next, a time course of protein expression and cytokine
secretion was examined in DCs transfected with the two
RNAs which induced the highest levels of secreted IL-12
(i.e., CD40L WT and CD40L ΔXE-MET1). The protein
expression level in cells transfected with ΔXE-MET1 RNA
is approximately two-fold greater at both 4 and 10 hrs
post-electroporation (Figure 6 panel D). Both conditions
resulted in almost undetectable intracellular CD40L
expression at 24 hrs post-electroporation. The difference
in duration of CD40L protein expression in the DCs
showed even greater differences in induced IL-12 secre-
tion. The total amount of the IL-12 cytokine secreted in 24
hours is almost a log greater in cultures transfected with
the optimized RNA compared to wild-type RNA. This
result is representative of several experiments performed
on independently prepared DCs cultures from different
donors.
Post-transcriptional capping modification produces 100% 
capped, highly translation competent RNA
Data presented above is consistent with this expectation
that induction of IL-12 secretion by DCs transfected with
CD40L ΔXE MET1 RNA is more robust when the RNA
contains an ARCA cap structure instead of an m7G cap
due to the inability of ARCA to be incorporated into the
inactive reverse orientation. Use of the ARCA cap ana-
logue during CD40L ΔXE MET1 RNA production would
address the problem of non-functional, reverse incorpora-
tion of the 5' cap. However, the final RNA product would
still contain a mixture of capped and uncapped RNA mol-
ecules. To test whether IL-12 induction can be elevated
even further we attempted to generate an RNA population
with near 100% capping efficiency and therefore, 100%
translationally competent.
The uncapped RNA was in vitro-transcribed from CD40L
ΔXE-MET1 template and Type 1 m7G-capped RNA was
generated. To measure the percent of capped RNA in a
total population an oligonucleotide-directed RNAseH
cleavage was performed. In this assay, the oligo anneals in
the proximity to the 5' end of the RNA such that the sizeBMC Molecular Biology 2008, 9:90 http://www.biomedcentral.com/1471-2199/9/90
Page 8 of 13
(page number not for citation purposes)
of the digested products are 19 nucleotides long if the
RNA was not capped and 20 nucleotides long if the RNA
was capped. The digested products can be radio-labelled
and visualized by PAGE analysis. The capping efficiency
measurements (Figure 7, Panel A) demonstrate quantita-
tive RNA capping by the Vaccinia virus capping enzyme.
This level of capping efficiency (100%) is never observed
following traditional co-transcriptional cap analogue
incorporation. Typically, co-transcriptional capping reac-
tions results in RNA populations which are 60–70%
capped when optimal conditions are used. In this experi-
ment a quantitative measure of capping efficiency of co-
transcriptionally capped RNA was 67% which is within
the expected range for this type of reaction. The upper
band in the uncapped RNA lane migrating above the band
21 nucleotide band is most likely a result of "RNA- oligo
hybrid breathing" or altered conformation perhaps due to
the absence of a cap structure. All of the RNAs were com-
pared to one another and also to the original CD40L RNA
in the IL-12 secretion assay (Figure 7 Panel B).
Consistent with previous observations the post-transcrip-
tionally capped CD40L ΔXE-MET1 RNA was more potent
for the induction of IL-12 secretion than the original con-
struct. This observation was confirmed in several assays
utilizing unique donor cellular materials (Table 1).
A comparative analysis of the post-transcriptionally
capped RNAs indicates that the post-transcriptionally
capped RNA has greater potency than either co-transcrip-
tionally capped counterpart. The molecular precursor for
the cap in the post-transcriptional reaction was GTP and
the resulting structure closely resembles the m7G cap.
However, 100% of the products of the post-transcrip-
CD40L protein lacking first naturally occurring Methionine codon induces highest levels of IL-12 secretion in DCs Figure 6
CD40L protein lacking first naturally occurring Methionine codon induces highest levels of IL-12 secretion in 
DCs. Panel A: SDS-Page Analysis of CD40L polypeptides translated in vitro obtained from RNAs with consecutively knocked 
out 1–4 methionine codons. No RNA: in vitro translation products of reaction containing no RNA template. C: translation of a 
positive control unrelated RNA Panel D: intracellular staining of DCs with anti-CD40L antibody of DCs harvested at indicated 
time point post-electroporation with either CD40L WT or CD40L ΔXE Met 1 RNAs as indicated on the bottom of the graph. 
Panel F: levels of IL-12 cytokine measured by ELISA accumulated in supernatants collected at indicated time point post-electro-
poration in DC cultures electroporated with either CD40L WT or CD40L ΔXE Met 1 RNAs. Each electroporation was per-
formed in triplicate. All CD40L RNAs were ARCA-capped with a long poly(A) tail. GFP is a negative control RNA.
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tional reaction using Vaccinia virus Capping enzyme are
in the correct orientation compared to 67% of ARCA
capped transcripts obtained in a co-transcriptional reac-
tion. Since both types of caps are in a translation-compe-
tent form, the highest translation competency is observed
in a population with greatest capping efficiency (i.e., post-
transcriptionally capped ΔXE-MET1 RNA).
Discussion
Untranslated sequences flanking an mRNA coding region
are known to contribute to the post-transcriptional regu-
lation of the RNA in eukaryotic cells, particularly with
regard to mRNA stability and translation. As a first step in
the improvement of translation efficiency of CD40L wild-
type RNA it was postulated that the presence of cryptic
ATG codons upstream of the correct ATG codon may cre-
ate competition between potential translation initiation
sites in the CD40L RNA that could lead to poor protein
expression or inaccurate translation initiation in trans-
fected DCs. This was confirmed by in vitro translation of
the RNA which produced protein products of different
molecular weights (Figure 4 panel B). This phenomenon
may contribute to the inconsistent expression of CD40L
protein levels required for high IL-12 induction. We
observed that removal of the cryptic ATG codons alone
increased the protein translation efficiency (Figure 5 panel
B). For each distinct RNA sequence, comparison of ARCA-
and m7G-capped RNAs demonstrated that ARCA-capped
RNAs produce higher levels of CD40L protein. This obser-
vation is consistent with previous reports [3,5,19]. Fur-
thermore, optimization of the Kozak sequence around the
naturally occurring ATG codon led to initiation of transla-
tion exclusively from the first methionine. Surprisingly,
this led to decreased levels of IL-12 by transfected DCs
compared to the DCs transfected with CD40L RNA with
an unoptimized Kozak sequence (Figure 5 panel B). In
contrast, the RNA generated from the template lacking the
first methionine produced higher protein levels and
resulted in greater levels of IL-12 (Figure 5 panel B). The
apparent correlation between predominance of the lower
molecular weight protein isoform and the ability to
induce high levels of IL-12 suggests that the small CD40L
isoform is the more active signalling molecule when
ectopically expressed in DCs.
Biological activity of a truncated recombinant 18 kDa
fragment of CD40L protein was demonstrated previously
[27]. Likewise the appearance of a shorter isoform was
Post-transcriptionally capped CD40L RNAs are 100% capped and induce the highest level of IL-12 secretion Figure 7
Post-transcriptionally capped CD40L RNAs are 100% capped and induce the highest level of IL-12 secretion. 
Panel A. Oligonucleotide-directed RNaseH cleavage products from the CD40L MET1 capping efficiency assay analyzed by 
denaturing polyacrylamide gel electrophoresis and autoradiography. Cleavage products from uncapped and capped RNA mole-
cules are denoted by arrows. The control RNA is co-transcriptional ARCA-capped ΔXE-MET1 RNA. Capping efficiency meas-
urements are indicated at the bottom of the gel image. Panel B: IL-12 cytokine secretion induced by ΔXE-MET1 RNA 
transfection as measured by ELISA. The resulting cap of each RNA is indicated by colour of the bars and as indicated, the type 
of cap (I or 0) is indicated below the graph. CD40L WT Reference RNA prepared with an ARCA cap by co-transcriptional cap 
analogue incorporation. GFP is a negative control RNA. All RNAs were polyadenylated post-transcriptionally and have >150 
nucleotide tails. non-standard format).
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attributed to utilization of one of the internal in-frame
methionines present in its sequence. The shorter protein
isoform was also more biologically active, however the
authors believed that the difference in activity was attrib-
utable to the more soluble nature of a shorter isoform ver-
sus the full-length protein. In our study, elimination of
the first methionine by site-directed mutagenesis led to a
deletion of the first 20 amino acids which does not predict
disruption of the transmembrane domain by the Kyte and
Doolittle hydropathy algorithm [28]. Another difference
between these two studies is the use of extracellularly
added recombinant form to the cell culture versus RNA
which is ectopically expressed inside the cell.
The majority of RNA made in in vitro transcription reac-
tions described so far utilize a co-transcriptional method
of RNA capping. The ratio of capped to uncapped RNA
produced can be modified by adjusting the ratio of cap
analogue to GTP present in the reaction. Increasing the
relative concentration of cap analogue enhances capping
efficiency, however, the concomitant decrease in the level
of GTP results in a lower yield of full-length product. The
use of the post-transcriptional capping method that we
employed results in a quantitative capping efficiency of
100% with all cap structures in the correct orientation.
Thus, each molecule in this RNA preparation is transla-
tionally-competent. The m7G Type 1 cap obtained in a
post-transcriptional capping reaction is indistinguishable
from the cap structure found at the 5' end of naturally
occurring mRNA's in eukaryotic cells and translation from
RNAs modified with this cap structure is significantly
enhanced compared to RNAs that do not contain the
methylated ribose (i.e. type 0) cap [29].
In addition to the synergistic effect on higher protein
expression, both the cap structure and poly(A) tail also
contribute to greater stability of the RNA [3]. The poly(A)
tail protects against initial degradation by exonucleases
which is followed by de-capping [30,31]. The notion that
greater poly(A) tail length can result in higher protein
expression is well established [32]. It would be of interest
to explore whether the difference in protein expression
observed from identical RNAs generated with different
cap structures is a consequence of the fact that one cap
structure may be more resistant to de-capping enzymes.
Interestingly, the absolute level of protein expression
measured at 4 hours post-transfection did not definitively
predict the level of IL-12 secreted by the same cells at 24
hours post-transfection. It is possible that the induction of
the IL-12 signalling pathway occurs at a time point later
than 4 hrs post-electroporation and we are achieving
greater steady-state levels as a result of increased RNA sta-
bility. Our routine Elisa assays studied IL-12 cytokine
secretion at 24 hours post-electroporation. Human clini-
cal studies examining intradermally administered
111indium-labeled DC migration show accumulation in
the lymph node after just 6 hours and continued accumu-
lation at 24 hrs and even 48 hrs post-injection [33,34]. It
would be of interest to understand whether continued IL-
12 secretion beyond 24 hours correlates with better clini-
cal outcome.
Finally, another advantage of the post-transcriptional
method is the ability to produce large amounts of
uncapped RNA precursor using in vitro transcription reac-
tions wherein the GTP nucleotide is not limiting. Tran-
scription reactions that employ co-transcriptional RNA
capping routinely include one-fourth the concentration of
GTP that a standard reaction contains and consequently
the final RNA yield from these reactions is approximately
four times less than the theoretical maximum. In the proc-
ess described here for CD40L MET1 RNA transcription, a
four- to five- fold increase in yield from the same DNA
template was obtained.
Conclusion
In summary we demonstrate various RNA modifications
that greatly improve the expression of CD40L protein
from in vitro transcribed RNA and which may be applied
to other RNAs for the purpose of enhancing protein
expression.
Methods
Cloning of CD40L
Normal volunteer's T cells were stimulated with PMA for
1 hr. After stimulation and wash cells were used for RNA
extraction. The RNA was taken into one tube RT-PCR reac-
tion using Gene Amp Gold kit (Applied Bioscience) sub-
stituting Gene Amp Gold Taq polymerase with Advantage
Polymerase (Clontech). One specific band of expected
size of 0.8 kb was obtained in the PCR reaction using the
following CD40L sequence specific primers: CD40L for-
ward: 5'-GCATGATCGAAACATACAACC-3' and CD40L
reverse : 5'-GTATTATGAAGACTCCCAGCG-3'.
Purified PCR fragment was subcloned into pCR2.1 vector.
Presence of specific sequence was verified by restriction
digest and sequencing. Results of the BLAST analysis per-
formed on the final sequence indicated identity to
sequence with accession # NM_000074 which is encoding
for CD40L. One exception was A to G transition at a
codon 102 of open reading frame which is silent and does
not result in a change in amino acid sequence and was left
unchanged.
Modification of 5' end of CD40L template DeltaXE 
construct and 5' UTR of CD40L
To construct the pCR2.1 CD40L ΔXE plasmid, the pCR2.1
CD40L plasmid was digested simultaneously with XbaIBMC Molecular Biology 2008, 9:90 http://www.biomedcentral.com/1471-2199/9/90
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and EcoRV (Promega). The XbaI overhang was subse-
quently filled with Klenow fragment of E. coli DNA
Polymerase I (IDT) in the presence of 30 μM dNTPs. Fol-
lowing gel purification of the 4738 base pair DNA frag-
ment was re-ligated using the FastLink DNA ligation kit
(Epicentre Biotechnologies).
To construct the pCR2.1 CD40L+5'UTR plasmid, the
pCR2.1 CD40L plasmid was used as a template in a PCR
reaction with the following oligonucleotide primers:
CD40L 5'UTR Forward
(5'ACGAATTCTTCTCTGCCAGAAGATACCATTTCAACTT
TAACACAGCATGATCGAAACATACAACC) and CD40L
3'UTR Reverse (5'CCAGTGTG
CTGGAATTCGGC) and Pfu Ultra Hot Start (Stratagene).
The resulting 890 bp PCR was then digested with EcoRI
(Promega), gel purified and was ligated to EcoRI-digested
pCR2.1 CD40L ΔXE plasmid. These manipulations
resulted in the addition of 39 bp of human CD40L 5' UTR
sequence 12 base pairs downstream of the transcription
initiation site.
Construction of the pCR2.1 CD40L+Kozak plasmid
involved PCR amplification of the pCR2.1 CD40L ΔXE
plasmid template with the primers CD40L Kozak F
(5'TCTGCAGAATTCGGCCACCATGATCGAAACATA) and
CD40L 3'UTR Rev using Pfu Ultra Hot Start. The 880 base
pair PCR product was digested with EcoRI and ligated to
EcoRI site of pCR2.1 CD40L ΔXE.
The accurate translation initiation site in pCR2.1 CD40L
ΔXE was mutated to create pCR2.1 CD40L ΔXE-MET1
using the QuickChange method described by Stratagene.
The oligonucleotides used for mutagenesis were CD40L
First Methionine F (5'CTGCAGAATTCGGCTTGCGCGAT
CGAAACATACAACC) and CD40L First methionine R
(5'GGTTGTATGTTTCGATCGCGCAAGCCGAATTCT-
GCAG). This manipulation resulted in substitution of GC
for AT in the CD40L first ATG codon. The changes were
confirmed by DNA sequencing.
All subsequent methionine mutagenesis experiments fol-
lowed the same procedure and resulted in a similar GC/AT
substitution. The template for the pCR2.1 CD40L ΔXE-
MET1,2 plasmid was pCR2.1 CD40L ΔXE-MET1 and the
oligonucleotides used were CD40L Second methionine F
(5'CACTGGACTGCCCATCAGCGCGAAAATTTTTATG-
TATTTACTTACTG) and CD40L Second methionine R
(5'CAGTAAGTAAATACATAAAAATTTTCGCGCTGAT-
GGGCAGTCCAGTG). The template for pCR2.1 CD40L
ΔXE-MET1,2,3 was pCR2.1 CD40L ΔXE-MET1 and the oli-
gonucleotides used were CD40L 2nd & 3rd methionine F
(5'CACTGGACTGCCCATCAGCGCGAAAATTTTTGCG-
TATTTACTTACTG) and CD40L 2nd & 3rd methionine R
(5'CAGTAAGTAAATACGCAAAAATTTTCGCGCTGAT-
GGGCAGTCCAGTG). The template for pCR2.1 CD40L
ΔXE-MET1–4 was pCR2.1 CD40L ΔXE-MET1,2,3 and the
oligonucleotides used were CD40L Fourth methionine F
(5'CTGTTTTTCTTATCACCCAGGCGATTGGGTCAGCACT
TTTTGC) and CD40L Fourth methionine R (5'GCAAAAA
GTGCTGACCCAATCGCCTGGGTGATAAGAAAAACAG).
In vitro transcription of CD40L RNA
Linear templates for in vitro transcription were prepared
by digesting each plasmid with SpeI (Roche). The linear
template was purified by phenol:chloroform extraction
followed by precipitation in ethanol and then resus-
pended in water.
Transcription reactions of co-transcriptionally capped
RNAs were performed using mMessage mMachine T7
Ultra (Ambion). Transcription reactions to produce
uncapped RNA were performed using T7 Flash Kit (Epi-
centre). Reactions were assembled as specified by each
kit's manufacturer. All in vitro transcribed RNAs were puri-
fied using Qiagen RNeasy Purification kits as directed by
the manufacturer.
Post-transcriptional capping of CD40L RNA
Post-transcriptional capping modification of uncapped
with type I cap CD40L MET1 RNA was performed using
ScriptCap Kit (Epicentre Biotechnologies) components
using capping buffer, GTP, SAM, Vaccinia Capping and
Vaccinia 2'O-Methyltransferase Enzymes.
Enzymatic polyadenylation of CD40L RNA
The polyadenylation was performed on purified RNA
using A-plus Poly(A) Tailing Kits (Epicentre Biotechnolo-
gies). Final RNAs were purified as described above and the
length of the poly(A) tail was determined by comparing
sizes of pre- polyadenylated and polyadenylated RNAs on
denaturing gel electropheresis. A typical preparation of
post-transcriptionally polyadenylated RNA contained
polyA tail of greater than 150 nucleotides.
In vitro translation of CD40L RNA in the presence of 35S-
Methionine
1 μg of RNA was heat denatured at 65°C for 3 minutes
and immediately cooled on ice. 25 uL reaction containing
the RNA and 1. 25 μL of Redivue 35S-labeled methionine
(Amersham) was assembled using Wheat Germ Extract Kit
(Promega) according to manufacturer's instruction. 1 μL
of each reaction was resolved on SDS Denaturing gel elec-
trophoresis and transferred onto PVDF membrane. The
membrane was exposed to phosphoimager screen and
image obtained by scanning using Storm imager (Amer-
sham).BMC Molecular Biology 2008, 9:90 http://www.biomedcentral.com/1471-2199/9/90
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Oligonucleotide-directed RNaseH cleavage products
2 μg of CD40L RNA and 32 pmol of the DNA oligonucle-
otide 5'CGCTCGAGCATGCAT/3ddC/3' (IDT) were first
denatured at 85°C for 4 minutes and then allowed to
hybridize for 4 hours at 42°C in 10 μL of RPA Hybridiza-
tion III Buffer (Ambion). Immediately after the hybridiza-
tion the RNA:DNA duplex was digested with 10 U E. coli
RNaseH (Ambion) for 1 hour at 25°C. The products of
the digestion were extracted with phenol:chloroform:iso-
amyl alcohol (25:24:1) and precipitated with sodium ace-
tate and ethanol in the presence of 20 μg glycogen
(Roche). The precipitate was washed with 70% ethanol,
allowed to air dry and then resuspended in water. 3'end
labeling was performed with 10 mCi/mL α32P-pCp (NEN
Perkin Elmer), T4 RNA ligase buffer and 1.25U T4 RNA
ligase (Ambion) for 12 -16 hours at 4°C. Labelled RNA
was purified using NucAway spin column (Ambion). RNA
samples were diluted with urea loading dye and resolved
on an 8M urea/15% polyacrylamide gel. Reaction prod-
ucts were visualized in the wet gel by phosphorimager
analysis and quantified using ImageQuant software.
Generation of Immature DCs
Human PBMCs were isolated from Leukapheresis collec-
tions from healthy volunteers by Ficoll-histopaque den-
sity centrifugation. PBMCs were re-suspended in AIM-V
medium (Invitrogen) and allowed to adhere to 150 cm3
plastic flasks for 2 hours at 37°C. Non-adherent cells were
removed and remaining cells cultured in X-vivo 15
medium, supplemented with 1000 U/ml GM-CSF (Leuk-
ine) and 1000 U/ml IL-4 (R&D systems), for 6 days at
37°C, 5% CO2.
Generation of cytokine cocktail matured DC
Prior to electroporation, DCs were harvested and washed
in PBS and then re-suspended in chilled Viaspan. DCs
were mixed with 2 μg of mRNA encoding GFP per million
cells.and placed in a 4 mm gap electroporation cuvette
and electroporated using BioRad apparatus. Immediately
after electroporation, DCs were washed in X-vivo-15
medium and finally re-suspended in X-vivo-15 supple-
mented with 800 U/mL GM-CSF and 500 U/mL IL-4 at 1
× 106/ml. Maturation was achieved by addition of 10 ng/
ml TNF-α, 10 ng/ml Il-1β, 100 ng/ml IL-6 and 1 μg/ml
PGE2 followed by culture for 24 hours at 37°C in low
adherence six well plates (BD Biosciences).
Generation of CD40L matured DCs
As described above, washed immature DC were re-sus-
pended in chilled Viaspan and mixed with varying
amounts of mRNAs encoding CD40L as described in
Results, and electroporated using BioRad apparatus. Post-
electroporation, DC were cultured in X-vivo-15 in the
presence of GM-CSF (800 U/ml) and IL-4 (500 U/ml)
plus 1000 U/mL IFN-γ and 1 μg/mL PGE2 for a further 24
hrs.
Intracellular detection of CD40L protein (CD154)
2 × 105 DCs were harvested post-transfection with CD40L
mRNA and re-suspended in 250μL of Cytofix/Cytoperm
solution (BD Biosciences) at 4°C. Cells were washed twice
with 2 mL staining buffer (PBS, BSA, NaN3, and EDTA),
re-suspended in 0.5 mL staining buffer and stored over
night at 4°C. Cells were re-suspended in 2.0 mL Perm/
Wash solution (BD Biosciences) for 15 minutes, centri-
fuged and re-suspended in 100μL Perm/Wash solution.
20μL of mouse anti-human CD40L PE and anti-human
CD40 APC (BD Biosciences) or mouse IgG1 PE and IgG1
APC (BD Biosciences) was added to each DCs preparation
collected and permeabilised at each time point, and incu-
bated at 4°C for 30 minutes in the dark. Cells were
washed twice with 1 mL Perm/Wash solution and re-sus-
pended in staining buffer prior to flow cytometric analy-
sis.
Quantitation of IL-12 secretion from mature DC 
populations
Mature DCs generated as described above, were immedi-
ately cultured post-electroporation at a concentration of 1
× 106 cells/ml and supernatants collected after 24 hrs for
the measurement of Il-12 or Il-10 secretion using BD
Pharmingen IL-12 or IL-10 ELISA kits. Briefly, ELISA
plates (BD Biosciences) were coated with anti-IL-12p70 or
anti-IL-10 ELISA capture antibody in coating buffer for 24
hours at 4°C using BD Opt EIA reagent set B pH 9.5.
Plates underwent blocking with 200μL per well 10%FCS/
PBS for one hour prior to the addition of standards (BD
Pharmingen) and supernatant samples, in duplicate, at
100μL per well and incubated at room temperature for 2
hrs. Plates were washed and anti-cytokine detection anti-
body added, incubated for one hour, the plates washed
and solutions replaced with 100 μL of streptavidin-HRP
and further incubated for one hour at room temperature.
Again plates were washed and colour development sub-
strates applied for 10–20 minutes, followed by cessation
of colour development with stop solution. Plate analysis
undertaken using Bio-Tek instruments ELx800 plate
reader with KC junior software.
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